Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036567 | 0.86 | LTA4H (0.43) | NPY1RHTTNPY2RLTA4H | |
| SCHEMBL4736470 | 0.86 | LTA4H (0.43) | NPY1RHTTNPY2RLTA4H | |
| SCHEMBL17606834 | 0.84 | LTA4H (0.44) | NPY1RHTTNPY2RLTA4H | |
| SCHEMBL652125 | 0.83 | HTR1A (0.47) | NPY1RHTTNPY2R | |
| SCHEMBL22605206 | 0.83 | HTR1A (0.47) | NPY1RHTTNPY2R | |
| SCHEMBL652126 | 0.83 | HTR1A (0.47) | NPY1RHTTNPY2R | |
| SCHEMBL10078725 | 0.83 | HTR1A (0.47) | NPY1RHTTNPY2R | |
| SCHEMBL1318062 | 0.82 | LTA4H (0.52) | NPY1RHTTNPY2RLTA4H | |
| SCHEMBL10053945 | 0.80 | HTR1A (0.45) | NPY1RHTTNPY2R | |
| SCHEMBL23539599 | 0.80 | SIGMAR1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4149937-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | NPY1R 2574/4885HTT 1/4885NPY2R 2339/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | NPY1R 2574/4885HTT 1/4885NPY2R 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.